

AMENDMENT

It is respectfully requested that the application be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS

Please add the following claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

--33. A method of treating T-cell mediated disease or infection comprising administering a medicament comprised of a *Notch* ligand to a patient in need thereof, wherein the T-cell mediated disease or infection is due to one or more of allergy, autoimmunity, graft rejection, tumor induced aberrations to the T-cell system, and infectious diseases.

34. A method of treating T-cell mediated disease or infection comprising administering a medicament comprised of a *Notch* ligand to a patient in need thereof, wherein the T-cell mediated disease or infection is due to one or more of allergy and graft rejection.

35. A method of treating T-cell mediated disease or infection comprising administering a medicament comprised of a *Notch* ligand to a patient in need thereof, wherein the T-cell mediated disease or infection is due to one or more of allergy, autoimmunity, and graft rejection.

36. A method of treating T-cell mediated disease or infection comprising administering a medicament comprised of a *Notch* ligand to a patient in need thereof, wherein the T-cell mediated disease or infection is due to graft rejection.

37. A method of treating T-cell mediated disease or infection comprising administering a medicament comprised of a *Notch* ligand to a patient in need thereof, wherein the T-cell mediated disease or infection is due to allergy.

sub E4 38. The method of treating T-cell mediated disease or infection of any of claims 27 or 28, or 33-37 wherein the *Notch*-ligand is selected from Serrate, or Delta.

39. The method of treating T-cell mediated disease or infection of any of claims 33-37, wherein the *Notch*-ligand is selected from Serrate, or Delta or fragments, derivatives or analogs thereof.

40. The method of any one of claims 30-32 wherein the *Notch*-ligand is selected from Serrate, or Delta or fragments, derivatives or analogs thereof.

41. The method of any one of claims 30-32 wherein the *Notch*-ligand is selected from Serrate, or Delta.--

Please cancel Claims 1-6 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.